Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Philogen SpA ( (IT:PHIL) ) is now available.
Philogen S.p.A. reported a significant financial turnaround in 2024, achieving record profits with revenues tripling from the previous year. The company is advancing its product pipeline with key developments including the ongoing evaluation of Nidlegy™ for melanoma by EMA, promising results in radiopharmaceuticals, and a new collaboration with Sun Pharma for Fibromun. These advancements underscore Philogen’s strengthened position in the biotechnology sector and its commitment to innovative cancer treatments.
More about Philogen SpA
Philogen S.p.A. is a biotechnology company focused on the development of innovative therapies for cancer treatment. The company is involved in research and development, with a market focus on cancer immunotherapy and radiopharmaceuticals.
YTD Price Performance: -2.11%
Average Trading Volume: 290
Technical Sentiment Signal: Sell
Current Market Cap: €580.5M
For a thorough assessment of PHIL stock, go to TipRanks’ Stock Analysis page.